Curry spices lower hypertension in rats, Indian research says

Credit: Rezwalker/Wikipedia. CC BY-SA 3.0

Indian medical researchers say they have successfully tested a blend of curry spices that lower blood pressure in lab rats, raising hopes for a natural and affordable drug to treat the chronic disease.

S. Thanikachalam, a cardiology expert who headed the research, said his team had tested a mixture of ginger, cardamom, cumin and pepper—common ingredients in Indian kitchens—along with white lotus petals and others on the rodents.

"We saw tremendous positive changes in rats induced with during our laboratory experiments," said Thanikachalam, who heads the department of cardiology at Sri Ramachandra University in the southern city of Chennai.

"The was very effective in reducing the blood pressure and bringing down oxidative stress in rats," he told AFP.

The study said the spices were successful at reducing renovascular hypertension, a secondary form of high caused by a narrowing of the arteries in the kidneys.

Indians are genetically predisposed to hypertension with one in four people in cities suffering from the disorder, according to the World Health Organisation (WHO).

Hypertension is mostly treated with modern pharmaceuticals but high costs and the possibility of side effects deter many from taking daily medication.

The latest research is not the first time a curry ingredient has been associated with healthy benefits.

In February 2011, scientists released a study suggesting a new hybrid drug tested on animals, made in part from the chemical in the yellow spice turmeric, could help regenerate brain cells after a stroke.

Thanikachalam said the herbal treatment tried by his team, known as venthamarai chooranam, was a combination mentioned in ancient Indian literature.

"It's been passed on from one generation to the other. It's just that it's not been validated scientifically," he said.

The researchers want to expand the animal study to see if the herbal medicine works for chronic conditions before turning to human clinical trials, a mandatory step before any new drug can be brought to market.

"We will be observing the rats in the long run and see if it sustains. Our goal is to develop a drug that is effective and cheap," he said."

The results of the study were published in the June edition of the medical journal Experimental Biology and Medicine.

add to favorites email to friend print save as pdf

Related Stories

Adempas approved to treat pulmonary hypertension

Oct 09, 2013

(HealthDay)—Adempas (riociguat) has been approved by the U.S. Food and Drug Administration to treat two types of pulmonary hypertension, characterized by high blood pressure in the arteries of the lungs.

Opsumit approved for pulmonary arterial hypertension

Oct 23, 2013

(HealthDay)—Opsumit (macitentan) has been approved by the U.S. Food and Drug Administration to treat adults with pulmonary arterial hypertension, a debilitating disease characterized by high blood pressure in the lung arteries.

Recommended for you

ASHG: MI without substantial CAD is minimally heritable

Oct 21, 2014

(HealthDay)—The presence of myocardial infarction (MI) without substantial coronary artery disease (CAD) is not familial, according to a study presented at the annual meeting of the American Society of ...

New treatment for inherited cholesterol

Oct 21, 2014

At the London Olympics in 2012, South African swimmer Cameron van den Burgh dedicated his world record-breaking win in the 100m breast stroke to one of his biggest rivals and closest friends, Alexander Dale ...

User comments